Hiveomics to Present External Validation Results at ESTS 2026 Congress
In modern radiology and thoracic oncology, one of the key challenges remains the differentiation between benign and malignant pulmonary nodules. With the increasing adoption of screening programs, particularly low-dose CT, the number of detected solitary pulmonary nodules continues to rise. However, not all of them represent a true oncological threat.
The landmark National Lung Screening Trial demonstrated a reduction in lung cancer mortality with CT screening. However, it also highlighted a critical issue: a high rate of overdiagnosis and unnecessary interventions. According to Fleischner Society data, up to 25% of patients without lung cancer undergo invasive procedures, including thoracoscopy and video-assisted thoracic surgery, due to false suspicion of malignancy.
This creates a clear clinical need for reliable tools capable of accurately identifying benign lesions and reducing unnecessary surgical interventions.
The Solution: Hiveomics AI Model
Hiveomics develops AI algorithms aimed at the non-invasive identification of benign pulmonary nodules, primarily:
- Hamartomas
- Intrapulmonary lymph nodes
An independent study was conducted to evaluate the model on a validation cohort of patients with confirmed diagnoses.
Key Results
The study reported:
- Intrapulmonary lymph node detection: sensitivity 90.9%, specificity 98.9%
- Hamartomas: sensitivity 68.75%, specificity 92.6%
- Overall performance for benign nodules: sensitivity 83.7%, specificity 89.3%
These results demonstrate that the model can accurately identify benign lesions, potentially reducing the number of unnecessary invasive diagnostic procedures.
International Recognition: ESTS 2026
The study abstract has been accepted at ESTS 2026, the annual conference of the European Society of Thoracic Surgeons.
ESTS is one of the leading professional organizations in thoracic surgery, bringing together experts from across Europe and beyond. The society plays a key role in shaping clinical standards, advancing education, and promoting the adoption of innovative technologies in thoracic disease management.
The annual ESTS Congress is a major international platform where:
- Cutting-edge scientific research is presented
- Modern diagnostic and treatment approaches are discussed
- Emerging technologies, including AI solutions, are evaluated
- Expert consensus influencing clinical practice is formed
Abstract selection undergoes rigorous peer review, making acceptance a strong indicator of scientific rigor and clinical relevance.
The acceptance of Hiveomics' external validation study at ESTS 2026 highlights the clinical relevance of the problem, the robustness of the validation results, and the potential for real-world clinical implementation.
Why It Matters
The use of AI solutions such as Hiveomics:
- Reduces the risk of overdiagnosis
- Decreases the number of unnecessary surgical interventions
- Increases clinician confidence in CT interpretation
- Supports a more personalized approach to patient management